Skip to content

Study · Animal study (in vivo) · mouse · 2019

16 results

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.

Zhang L, Zhang L, Li L, Hölscher C

Journal of Parkinson's disease1 Jan 2019Cited by 141 (Europe PMC)

PMID30741689 (opens in a new tab)DOI10.3233/jpd-181503 (opens in a new tab)PepBankPUB-30741689
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In the chronic MPTP mouse model of Parkinson's disease, semaglutide improved MPTP-induced motor impairments.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide improved movement problems.

    Peptide
    Semaglutide
    Outcome
    DecreaseMPTP-induced motor impairment
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Our results show that both semaglutide and liraglutide improved MPTP-induced motor impairments.
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, semaglutide rescued the MPTP-induced decrease of tyrosine hydroxylase levels.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide restored a nerve-cell enzyme (TH) that the toxin had lowered.

    Peptide
    Semaglutide
    Outcome
    IncreaseTyrosine hydroxylase level
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    rescued the decrease of tyrosine hydroxylase (TH) levels
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, semaglutide reduced the accumulation of alpha-synuclein.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide reduced build-up of a harmful protein (alpha-synuclein).

    Peptide
    Semaglutide
    Outcome
    DecreaseAlpha-synuclein accumulation
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Title
    Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
    2 context sentences
    Summary · context
    reduced the accumulation of α-syn
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, semaglutide alleviated the chronic inflammation response in the brain.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide eased long-term brain inflammation.

    Peptide
    Semaglutide
    Outcome
    DecreaseChronic brain inflammation
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    alleviated the chronic inflammation response in the brain
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, semaglutide reduced lipid peroxidation.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide lowered a sign of cell damage from oxidation (lipid peroxidation).

    Peptide
    Semaglutide
    Outcome
    DecreaseLipid peroxidation
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Oxidative stress · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    reduced lipid peroxidation
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, semaglutide inhibited the mitochondrial mitophagy signaling pathway.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide dampened a cell pathway that clears damaged mitochondria (mitophagy).

    Peptide
    Semaglutide
    Outcome
    DecreaseMitochondrial mitophagy signaling pathway
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    inhibited the mitochondrial mitophagy signaling pathway
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, semaglutide increased expression of the growth factor GDNF in the substantia nigra and striatum.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide raised a nerve-protecting growth factor (GDNF) in two brain areas.

    Peptide
    Semaglutide
    Outcome
    IncreaseGDNF expression
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    furthermore increased expression of the key growth factor GDNF that protects dopaminergic neurons in the substantia nigra (SN) and striatum
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In the chronic MPTP mouse model of Parkinson's disease, liraglutide improved MPTP-induced motor impairments.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide improved movement problems.

    Peptide
    Liraglutide
    Outcome
    DecreaseMPTP-induced motor impairment
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Our results show that both semaglutide and liraglutide improved MPTP-induced motor impairments.
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, liraglutide rescued the MPTP-induced decrease of tyrosine hydroxylase levels.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide restored a nerve-cell enzyme (TH) that the toxin had lowered.

    Peptide
    Liraglutide
    Outcome
    IncreaseTyrosine hydroxylase level
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    rescued the decrease of tyrosine hydroxylase (TH) levels
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, liraglutide reduced the accumulation of alpha-synuclein.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide reduced build-up of a harmful protein (alpha-synuclein).

    Peptide
    Liraglutide
    Outcome
    DecreaseAlpha-synuclein accumulation
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Title
    Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
    2 context sentences
    Summary · context
    reduced the accumulation of α-syn
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, liraglutide alleviated the chronic inflammation response in the brain.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide eased long-term brain inflammation.

    Peptide
    Liraglutide
    Outcome
    DecreaseChronic brain inflammation
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    alleviated the chronic inflammation response in the brain
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, liraglutide reduced lipid peroxidation.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide lowered a sign of cell damage from oxidation (lipid peroxidation).

    Peptide
    Liraglutide
    Outcome
    DecreaseLipid peroxidation
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Oxidative stress · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    reduced lipid peroxidation
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, liraglutide inhibited the mitochondrial mitophagy signaling pathway.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide dampened a cell pathway that clears damaged mitochondria (mitophagy).

    Peptide
    Liraglutide
    Outcome
    DecreaseMitochondrial mitophagy signaling pathway
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    inhibited the mitochondrial mitophagy signaling pathway
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In the chronic MPTP mouse model, liraglutide increased expression of the growth factor GDNF in the substantia nigra and striatum.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide raised a nerve-protecting growth factor (GDNF) in two brain areas.

    Peptide
    Liraglutide
    Outcome
    IncreaseGDNF expression
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    furthermore increased expression of the key growth factor GDNF that protects dopaminergic neurons in the substantia nigra (SN) and striatum
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In the chronic MPTP mouse model, semaglutide was more potent than once-daily liraglutide in most parameters measured.

    In plain wordsIn mice with Parkinson's-like disease, semaglutide worked better than liraglutide on most measures.

    Peptide
    Semaglutide
    Outcome
    Not applicablePotency versus liraglutide across measured parameters
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Comparator
    Liraglutide 25 nmol/kg once daily
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once every two days · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, the long- acting GLP-1 analogue semaglutide was more potent compared with once daily liraglutide in most parameters measured in this study.
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In the chronic MPTP mouse model, once-daily liraglutide was less potent than semaglutide in most parameters measured.

    In plain wordsIn mice with Parkinson's-like disease, liraglutide worked less well than semaglutide on most measures.

    Peptide
    Liraglutide
    Outcome
    Not applicablePotency versus semaglutide across measured parameters
    Study

    mousen: not reported in source

    Chronic MPTP mouse model of Parkinson's disease
    Comparator
    Semaglutide 25 nmol/kg once every two days
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    25 nmol/kg once daily · intraperitoneal · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, the long- acting GLP-1 analogue semaglutide was more potent compared with once daily liraglutide in most parameters measured in this study.
    1 context sentence
    Summary · context
    In the present study, we have investigated the neuroprotective effects of the GLP-1 analogues semaglutide (25 nmol/kg ip. once every two days for 30 days) and liraglutide (25 nmol/kg ip. once daily for 30 days) in the chronic MPTP mouse model of PD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.